Finoriq

Finoriq research workspace

Bolt Biotherapeutics, Inc. (BOLT) Insider Transactions & Form 4 Activity

Track insider acquisitions, dispositions, options, RSUs, and Form 4 activity for Bolt Biotherapeutics, Inc. (BOLT).

Company Snapshot

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory. The company has collaboration agreements with Toray Industries, Genmab A/S, and Innovent Biologics, Inc.; and a license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

Company
Bolt Biotherapeutics, Inc. (BOLT)
Ticker
BOLT
Market Cap
$8.5M
Latest Price
$4.43
Industry
Biotech & Pharma

Open company research

Bolt Biotherapeutics, Inc. (BOLT) Recent Insider Transactions

Recent market insider transaction records indexed for Bolt Biotherapeutics, Inc. (BOLT).

InsiderCodeValueTransaction Date
Quinn William P.President, CEO and CFOP | Acquired$5762025-12-05
Nemec SarahSenior VP, Finance and PAOP | Acquired$5762025-12-05

Live data loads in the app

This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.